

Huntington's Disease: A Nursing Perspective

Sarah V Samperi ; Peter Kwong ; Terence McGill ; David S Tsui



Tetrabenazine is not the only drug registered by the FDA for the treatment of Chorea in Huntington's disease. On the 3rd April 2017 Deutetrabenazine (trade name Austedo) was approved by the U.S. Food & Drug Administration (FDA) for the treatment of chorea associated with Huntington's Disease (U.S. Department of Health and Human Services, 2017). On the 2nd June 2021 Deutetrabenazine (product name Austedo) was entered on in the treatment of pembrolizumab-induced

myasthenia gravis. Eur J Cancer Oxf Engl
o the Australian Registry of Therapeutic
Goods for the treatment of chorea associated
with Huntington's Disease (Australian Gov-
ernment, 2021).

Australian Government: Department of
Health, Therapeutic Goods Administration.
(2021). Austedo. [Austedo | Therapeutic
Goods Administration \(TGA\)](#)

U.S. Department of Health and Human Ser-
vices: U.S. Food & Drug Administration
(2017). FDA-Approved Drugs. [https://
www.accessdata.fda.gov/scripts/cder/daf/
index.cfm?
event=overview.process&ApplNo=208082](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208082)

The poster for the 2022 conference of the Australasian Neuroscience Nurses' Association. It features a background image of a scuba diver swimming over a large, green, brain-like coral structure. The text is arranged in a green and blue layout. The top left has the association's logo. The top right says '2022 Conference'. The middle left says 'Australasian Neuroscience Nurses' Association'. The bottom left says 'DIVING INTO NEUROSCIENCE NURSING - just keep swimming!'. The bottom right says 'Save the date! 10-11 November, Melbourne, Victoria'.